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Background: Plasmodium knowlesi, a malaria parasite of Southeast Asian macaques, infects humans and can cause
fatal malaria. It is difficult to diagnose by microscopy because of morphological similarity to Plasmodium malariae.
Nested PCR assay is the most accurate method to distinguish P. knowlesi from other Plasmodium species but is not
cost effective in resource-poor settings. Rapid diagnostic tests (RDTs) are recommended for settings where malaria
is prevalent. In this study, the effectiveness of three RDTs in detecting P. knowlesi from fresh and frozen patient
blood samples was evaluated.
Methods: Forty malaria patients (28 P. knowlesi, ten P. vivax and two P. falciparum) diagnosed by microscopy were
recruited in Sarawak, Malaysian Borneo during a 16-month period. Patient blood samples were used to determine
parasitaemia by microscopy, confirm the Plasmodium species present by PCR and evaluate three RDTs: OptiMAL-IT,
BinaxNOW® Malaria and Paramax-3. The RDTs were also evaluated using frozen blood samples from 41 knowlesi
malaria patients.
Results: OptiMAL-IT was the most sensitive RDT, with a sensitivity of 71% (20/28; 95% CI = 54-88%) for fresh and
73% (30/41; 95% CI = 59-87%) for frozen knowlesi samples. However, it yielded predominantly falciparum-positive
results due to cross-reactivity of the P. falciparum test reagent with P. knowlesi. BinaxNOW® Malaria correctly detected
non-P. falciparum malaria in P. knowlesi samples but was the least sensitive, detecting only 29% (8/28; 95% CI = 12-46%)
of fresh and 24% (10/41; 95% CI = 11-37%) of frozen samples. The Paramax-3 RDT tested positive for P. vivax with
PCR-confirmed P. knowlesi samples with sensitivities of 40% (10/25; 95% CI = 21-59%) with fresh and 32% (13/41;
95% CI = 17-46%) with frozen samples. All RDTs correctly identified P. falciparum- and P. vivax-positive controls
with parasitaemias above 2,000 parasites/μl blood.
Conclusions: The RDTs detected Plasmodium in P. knowlesi-infected blood samples with poor sensitivity and
specificity. Patients with P. knowlesi could be misdiagnosed as P. falciparum with OptiMAL-IT, P. vivax with
Paramax-3 and more correctly as non-P. vivax/non-P. falciparum with BinaxNOW® Malaria. There is a need for a sensitive
and specific RDT for malaria diagnosis in settings where P. knowlesi infections predominate.
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Until recently only four types of Plasmodium (Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae
and Plasmodium ovale) were known to cause malaria in
humans. However, a fifth species, Plasmodium knowlesi,
has been identified as a cause of human malaria in almost* Correspondence: bskhaira55@gmail.com
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unless otherwise stated.all countries in Southeast Asia (recently reviewed [1]) and
extending to the Nicobar and Andaman Islands in India
[2]. In Malaysian Borneo, P. knowlesi is the main cause
of admissions for malaria in certain hospitals, including
Sarikei Hospital, and can lead to fatal infections [3-9].
Plasmodium species infections are typically diagnosed
by microscopic examination of stained blood films, but
there are limitations in sensitivity and specificity [10].
Nested PCR assays were developed to accurately distinguishtd. This is an Open Access article distributed under the terms of the Creative
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most sensitive detection method for malaria and can
distinguish P. knowlesi from the morphologically similar
P. malariae [11,12]. However, both microscopy and espe-
cially nested PCR assays require significant resources,
such as specialized equipment, electricity and skilled
technicians. PCR methods are not recommended for
malaria diagnosis in resource-poor settings.
Malaria antigen-based rapid diagnostic tests (RDTs),
mainly for the detection of P. falciparum, were developed
for use in remote areas with limited facilities. A large
number of RDTs are available for malaria diagnosis,
including OptiMAL-IT produced by DiaMed, CA, USA
[13,14], BinaxNOW® Malaria produced by Inverness
Medical, FL, USA [15,16], and Paramax-3 malaria Pf/
Pv/Pan from Zephyr Biomedical Systems, India [17,18].
The OptiMAL-IT test strip contains the antibody 17E4,
which specifically detects P. falciparum lactate dehydro-
genase (pLDH) and a pan-malaria antibody (19G4) that
identifies pLDH from P. vivax, P. malariae and P. ovale as
well as P. falciparum. BinaxNOW® Malaria is the only
test approved by the US FDA and contains an antibody
that detects P. falciparum-specific histidine rich protein
2 (HRP-2) and a pan-malaria antibody that detects
Plasmodium aldolase, a glycolytic enzyme produced by
all species of the parasite. The Paramax-3 test strip
contains three antibody test lines as well as a control
line: an antibody detecting P. falciparum HRP-2, similar
to the BinaxNOW® Malaria test, a pan-malaria pLDH
antibody, and an antibody specific for P. vivax LDH.
None of the tests include P. knowlesi-specific reagents.
OptiMAL-IT, and another RDT under development [19],
have been shown to detect P. knowlesi under experimental
conditions. An imported case of human P. knowlesi
from Sarawak to the Netherlands with 2% parasitaemia
(84,000 trophozoites/μl) gave positive results for both
the P. falciparum-specific LDH and pan-malarial LDH test
lines, suggesting cross-reactivity between P. knowlesi LDH
and the monoclonal antibody used in the test to detect
P. falciparum LDH [20]. This cross-reactivity was first
reported by McCutchan et al. [19], was also noted by
Kawai et al. using P. knowlesi-infected Japanese macaque
blood samples with OptiMAL-IT [21] and by Ong et al.
using a P. knowlesi-positive blood sample from a patient
with 0.2% parasitaemia [22].
BinaxNOW® Malaria has been used to detect P. knowlesi
in several case reports with varying results [20,22-25]. In a
case of P. knowlesi malaria imported into the Netherlands,
BinaxNOW® Malaria but not OptiMAL-IT gave a positive
result for non-P. falciparum malaria [20]. Similar results
were reported in another case [23]. However, BinaxNOW®
can also cross react and show falciparum-positive results,
as observed with a P. knowlesi-infected patient with
0.2% parasitaemia [22]. False-negative results were alsoobtained using this test with two P. knowlesi malaria
patients with parasitaemia of 0.0005 and 0.1% [24,25],
suggesting that BinaxNOW® Malaria may be less sensitive
than OptiMAL-IT.
None of the aformentioned studies has evaluated the
Paramax-3 test with P. knowlesi samples. The objective
of this study was to evaluate three RDTs, OptiMAL-IT,
BinaxNOW® Malaria, and Paramax-3, in the detection of
P. knowlesi infection from both fresh and frozen blood
samples from knowlesi malaria patients.
Methods
Study sites
All consecutive malaria-positive patients, diagnosed by
microscopy, were recruited following acquisition of in-
formed consent at Sarikei Polyclinic and Sarikei Hospital
in the town of Sarikei, Sarawak, Malaysian Borneo. The
study was approved by the Malaysian Ministry of Health’s
Medical Research and Ethics Committee.
Collection and processing of fresh and frozen blood samples
A total of 40 malaria-positive blood samples were col-
lected between March 2010 and July 2011: ten (seven
P. knowlesi and three P. vivax) from Sarikei Polyclinic
and 30 (21 P. knowlesi, seven P. vivax and two P. falcip-
arum) from Sarikei Hospital. No mixed species infections
were identified. Venous blood samples collected from
these patients were used to make thick and thin blood
films for verification of parasitaemia by microscopy, blood
spots on filter paper for malaria species identification by
nested PCR assays, and to evaluate RDTs.
The three RDTs were also evaluated using 44 frozen
whole-blood samples collected from malaria patients
with PCR-confirmed P. knowlesi (N = 41), P. falciparum
(N = 3) and P. vivax (N = 1), admitted to Sarikei and
Sibu Hospitals in the two years prior to the start of this
study and from those recruited during a previous study
at Kapit Hospital [26]. Whole-blood samples, stored at
−80°C, were thawed and used to evaluate the RDTs as
recommended.
Analysis of samples by microscopy
Thick blood films from samples acquired at Sarikei Poly-
clinic and Hospital were allowed to dry overnight, then
stained with 3% Giemsa for 45 minutes. Thin blood
films were fixed with methanol and stained with 10%
Giemsa for 30 minutes. Parasitaemia was later deter-
mined by an experienced microscopist. Parasitaemia was
calculated as the number of parasites per μl of blood for
each sample by using each patient’s actual white blood
cell (WBC) count, and by counting up to 500 WBCs in
thick blood films and the corresponding number of
malaria parasites.
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DNA was extracted from the blood spots on filter paper
using the Instagene method [26]. All samples were ini-
tially examined by PCR assay using the Plasmodium
genus-specific primers rPLU1 and rPLU5 for the Nest 1
amplification, which targets the small sub-unit ribosomal
RNA gene of the Plasmodium genus [21]. Reaction mix-
tures for no more than ten samples were prepared and
processed at one time and a positive and negative control
were processed with each batch of samples to maintain
high-quality control.
In order to identify the malaria species present in each
sample, Nest 1 amplification products were screened using
Nest 2 species-specific primers, as described previously
[12,26,27] for each of the five species of malaria known
to infect humans: P. falciparum, P. vivax, P. malariae,
P. ovale and P. knowlesi. For the species-specific primer
pairs for P. falciparum, P. vivax, P. malariae and P.
ovale (rFAL1/rFAL2, rVIV1/rVIV2, rMAL1/rMAL2, and
rOVA1/rOVA4) the annealing temperature was 58°C, and
for the P. knowlesi-specific primer pair (kn1f and kn3r)
the annealing temperature was 62°C. The Nest 2 products
were analysed using agarose gel (2.5%) electrophoresis and
Sybr green® staining (1x concentration for 30 minutes),
viewed via UV transilluminator, photographed for docu-
mentation and recorded.
Analysis of samples by RDTs
The three antigen-based RDTs, OptiMAL-IT, BinaxNOW®
Malaria, and Paramax-3, were used according to the
manufacturers’ instructions. Fresh blood samples from
malaria patients were processed within three hours of
collection, and immediately when using thawed frozen
blood samples. Thawed samples were processed as for
fresh blood. OptiMAL-IT requires 10 μl of blood and
takes 20 minutes to complete, BinaxNOW® Malaria
requires 15 μl of blood and takes 10–15 minutes to
complete, and Paramax-3 requires 5 μl of blood and
takes 15 minutes to complete. Tests were interpreted
as successful when the control band was positive.
Analysis of results of RDTs
The sensitivity of each RDT was calculated with PCR
results as the reference standard. The 95% confidence
interval (CI) for each test was calculated based on the
test sensitivity and number of tests performed using 1.96
as the standard normal deviate (using the formula: 95%
CI = Sensitivity ± 1.96 × standard error of the test) [28].
Results
RDTs were evaluated against 40 microscopy-positive
fresh blood samples (identified by nested PCR assay as
28 P. knowlesi, two P. falciparum and ten P. vivax),
along with 44 frozen whole-blood malaria samples (41 P.knowlesi, two P. falciparum and one P. vivax by nested
PCR assay). All RDTs were successful in that the control
line was positive on all tests performed.
In total, 28 OptiMAL-IT and BinaxNOW® Malaria
and 25 Paramax-3 tests were performed on P. knowlesi
field isolates (median parasitaemia = 9,131 parasites/μl;
range = 159–911,616 parasites/μl blood) and 41 of each
RDT were performed using frozen P. knowlesi samples
(median parasitaemia = 1,297 parasites/μl; range = 10–
188,384 parasites/μl blood).
OptiMAL-IT was the most sensitive of the three RDTs
evaluated, with a sensitivity of 71% (20/28; 95% CI = 54-
88%) and 73% (30/41; 95% CI = 59-87%) for fresh and
frozen knowlesi malaria samples, respectively (Tables 1
and 2). However, the test was not specific and P. knowlesi
samples cross-reacted with the P. falciparum LDH test
reagent in 18 of the 20 fresh samples identified. Only
two of the fresh P. knowlesi samples were identified as
non-P. falciparum malaria using OptiMAL-IT.
BinaxNOW® Malaria showed the lowest sensitivity,
detecting only 29% (8/28; 95% CI = 12-45%) of fresh
and 24% (10/41; 95% CI = 11-37%) of frozen samples.
This test was negative for all ten P. knowlesi fresh blood
samples with parasitaemia <5,000 parasites/μl and also
tested negative for 56% (10/18) of fresh samples with para-
sitaemia >5,000 parasites/μl (Table 1). However, with the
BinaxNOW® Malaria test, which detects P. falciparum-
specific histidine rich protein 2 (HRP-2), all positive
results for P. knowlesi cases were correctly identified as
non-P. falciparum malaria infections.
The Paramax-3 test also had low sensitivities of 40%
(10/25; 95% CI = 21-59% ) and 32% (13/41; 95% CI = 18-
46%) for fresh and frozen P. knowlesi samples, respectively.
Of the ten Paramax-3 tests that yielded positive results
with fresh blood samples, one indicated a P. falciparum
infection, one indicated a non-P. falciparum, non-P. vivax
result and the remaining eight gave results indicating
P. vivax infections (Table 2).
Plasmodium vivax (N = 10) and P. falciparum (N = 2)
samples from Sarikei Hospital and Polyclinic were collected
for testing with RDTs as positive controls. All three RDTs
gave positive results accurate for the species present when
the parasitaemias were above 2,000 parasites/μl blood
(range: 240–23,000 parasites/μl). The RDTs did not detect
samples with P. vivax (N = 2) or P. falciparum (N = 1) para-
sitaemia less than 2,000 parasites/μl. All frozen P. vivax
(N = 1) and P. falciparum (N = 2) positive controls yielded
positive RDT results appropriate for the species. The
parasitaemia for these samples was relatively high (19,000-
30,000 parasites/μl).
Discussion
Among the RDTs tested in this study, the OptiMAL-IT
test was the most sensitive for P. knowlesi-infected blood
Table 1 Rapid diagnostic test results for Plasmodium knowlesi fresh blood from field isolates
P. knowlesi parasitaemia
(parasites/μl)






















Negative 4 Negative 10 Negative 9
1,001-5,000 Pf-positive
(Pf and Pan-positive)













Negative 2 Negative 7 Negative 3
501-1,000 Pf-positive
(Pf and Pan-positive)













Negative 2 Negative 2 Negative 2
1-500 Pf-positive
(Pf and Pan-positive)













Negative 0 Negative 1 Negative 1
Total Pf-positive
(Pf and Pan-positive)













Negative 8 Negative 20 Negative 15
Total tested 28 28 25
Total positive 20 8 10
Sensitivity 71% 29% 40%
(95% CI) (54 – 88%) (12 – 46%) (21 – 59%)
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majority of P. knowlesi samples were identified as P.
falciparum by this test due to antibody cross-reactivity,
as noted in previous studies [19-22]. BinaxNOW® Malaria
was found to be the least sensitive of the three RDTs
assessed, but there was no cross-reactivity observed
between the P. falciparum antibody for P. falciparum-
HRP-2 and P. knowlesi samples. In this study, all positive
results attained using this test with P. knowlesi-confirmedsamples correctly indicated a non-P. falciparum malaria
infection. The Paramax-3 test showed low sensitivity
and cross-reactivity between the P. vivax LDH-detecting
antibody and P. knowlesi. This observation has been noted
in several other single case reports using different tests
which also contain a P. vivax LDH-detecting antibody
[19,23,24].
The sensitivity of detecting P. knowlesi in blood samples
with all three RDTs assessed in this study was significantly
Table 2 Rapid diagnostic test results from frozen Plasmodium knowlesi blood samples
P. knowlesi parasitaemia
(parasites/μl)






















Negative 0 Negative 3 Negative 1
1,001-5,000 Pf-positive
(Pf and Pan-positive)













Negative 0 Negative 11 Negative 9
501-1,000 Pf-positive
(Pf and Pan-positive)













Negative 4 Negative 6 Negative 7
1-500 Pf-positive
(Pf and Pan-positive)













Negative 7 Negative 11 Negative 11
TOTAL Pf-positive
(Pf and Pan-positive)













Negative 11 Negative 31 Negative 28
Total tested 41 41 41
Total positive 30 10 13
Sensitivity 73% 24% 32%
(95% CI) (59 – 87%) (11 – 37%) (17 – 46%)
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example, the sensitivity of detection of P. falciparum using
OptiMAL-IT has been reported as 95.3% (100% for >500
parasites/μl and 72% for 50 parasites/μl) and 96% for
P. vivax malaria infections [14]. For BinaxNOW® Malaria,
the sensitivity of detection for P. falciparum has been
reported as 95.3% (99.7% for >5,000 parasites/μl and
53.9% for 100 parasites/μl or fewer) and 68.9% for P. vivax
malaria infections [16]. For Paramax-3, the sensitivity andspecificity of detection for both P. falciparum and P. vivax
malaria infections is reported as 100% in an in-house study
of 251 samples [29]. Although the number of positive
controls conducted in this study was relatively low,
none of the RDTs used in this study detected P. vivax
or P. falciparum infections in fresh blood samples with
parasitaemias less than 2,000 parasites/μl.
One limitation of this study is the relatively low num-
bers of fresh samples tested. To strengthen the results
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cluded. The sensitivity of detection of knowlesi malaria
infections with the RDTs tested were fairly similar using
fresh versus frozen samples. Freeze-thawing and the
storage of blood at low temperatures can accelerate
deterioration of antigen activity, although it is also possible
that target antigens are more accessible in freeze-thawed
samples and may actually improve the sensitivity of
RDTs [30].
A recently published paper from Sabah, Malaysian
Borneo presents the use of two different RDTs, First
Response™, which detects pan-Plasmodium LDH and
Pf-specific HRP-2, and ParaHIT™, which detects pan-
Plasmodium aldolase and Pf-specific HRP-2 [7]. A total
of 129 P. knowlesi patient samples were studied, only 34 of
whom were enrolled in the study prior to treatment, while
the remainder were referred from district hospitals where
they had already received anti-malarial treatment [7]. The
findings of this study indicated a sensitivity of 74% for the
pLDH component of the First Response™ RDT, which is
similar to that observed in the current study with
OptiMAL-IT (71 and 73% sensitivity with fresh and frozen
samples, respectively), and higher than that observed with
the Paramax-3 test (40 and 32% sensitivity), both of which
also detect pLDH. In the current study as well as the one
in Sabah, the RDTs with the pan-aldolase component had
the lowest sensitivity of detection of P. knowlesi samples;
29% with the ParaHIT™ test [7], and 29% with fresh and
24% with frozen samples using the BinaxNOW® Malaria
RDT.
RDTs cost between 10 and 15 Malaysian Ringgit (US
$3.17-4.80) per test when purchased at a dispensary in
Malaysia. Although when purchased in bulk for malaria
control programs this cost tends to be significantly re-
duced, microscopy is still the most affordable diagnostic
tool and costs just one Ringgit (US$0.30) per patient to
screen for malaria. The cost of nested PCR assay is
comparable to RDTs per patient sample, and although
PCR assay is significantly more sensitive and specific
than microscopy, this technique requires specialized
equipment, electricity supply and training, and is not
suitable for resource-poor settings. RDTs confer the
advantages of speed (all types used in this study took
20 minutes or less to conduct), minimal training and ease
of use, and do not require electricity or any specific hard-
ware. However, currently available RDTs lack sensitivity
and specificity compared to microscopy and PCR-based
methods for all Plasmodium species infections, especially
P. knowlesi. The development of loop-mediated isothermal
amplification (LAMP) assays combine the sensitivity and
specificity of PCR with low cost, low technology and rapid
results. LAMP-based tests for malaria diagnosis that in-
clude reagents specific for P. knowlesi are under develop-
ment and may be useful for resorce-poor settings [31,32].In areas with relatively low malaria prevalence such as
Sarawak, the cost of RDTs, even if sensitive and specific,
would likely outweigh the benefit. To understand this in
practical terms, consider, for example, the case of Julau
Health Clinic, which is a small, rural health clinic in
Sarawak surveyed as part of the current study. The
prevalence of malaria at this clinic during a five-month
study period in which 108 febrile patients whose clinical
presentations were suggestive of malaria were screened
using nested PCR assay was 0.2% (Foster et al., unpub-
lished data). As such, it would have cost between MYR
1,080 and 1,620 (US$342-832) to perform RDTs for these
108 query malaria patients and only two were positive.
This study confirms that the RDTs evaluated are not
adequately sensitive for use in the diagnosis of P. knowlesi.
Also, P. knowlesi cross-reacted with P. falciparum and
P. vivax LDH antibodies used in two of the three com-
mercially available RDTs tested, resulting in misdiagnosis
of malaria species in an area where human P. knowlesi
infections are prevalent. Since not all species of malaria
warrant the same level of medical care, misidentification
can result in mismanagement, especially when the poten-
tially severe knowlesi malaria is misdiagnosed as vivax
malaria. Because P. knowlesi is morphologically similar to
P. malariae and P. falciparum, it is also misdiagnosed by
microscopy [10,23,24]. However microscopy should not
be replaced by RDTs in areas where P. knowlesi occurs
until the sensitivity, specificity and costs are comparable.Conclusions
The sensitivity of detection of P. knowlesi by the three
RDTs evaluated is low compared with microscopy. Cross-
reactivity is common between P. knowlesi-infected blood
and both the P. falciparum-detecting antibody used in the
OptiMAL-IT test and the P. vivax-detecting antibody used
in the Paramax-3 test. As such, a patient with knowlesi
malaria may be diagnosed as P. falciparum by OptiMAL-
IT, as P. vivax by Paramax-3 and as non-P.vivax and
non-P. falciparum by BinaxNOW® Malaria. Until more
sensitive RDTs are developed that can distinguish P.
knowlesi from P. falciparum and P. vivax, serious con-
sideration should be taken before using RDTs for the
diagnosis of malaria in settings where P. knowlesi is the
predominant species.
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